HURA on Nasdaq

TuHURA Biosciences, Inc./NV

American pharmaceutical preparations company based in Tampa.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

  • TickerHURA on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersNV
  • Incorporated inNV2
  • Business address10500 University Center Dr., Suite 110, Tampa, Fl 336122
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-143.6%Return on equity3
-$27.7MFree cash flow3

Financial statements

Revenue43$0 in 2025
02023: $0$020232024: $0$020242025: $0$02025
Net income567843-$30.1M in 2025+273% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$8.0M-$8.0M20192020: -$9.1M-$9.1M2020+13%2021: -$38.3M-$38.3M2021+320%2022: -$22.7M-$22.7M2022−41%2023: -$29.3M-$29.3M2023+29%2024: -$21.7M-$21.7M2024−26%2025: -$30.1M-$30.1M2025+39%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Research and development expenses$20.5M$13.3M
Acquisition-related costs (note 5)$3.7M$440.3K
General and administrative expenses$7.6M$3.9M
Operating Loss-$31.8M-$17.6M
Employee Retention Tax Credit$113.6K
Grant income$713.5K$57.6K
Interest expense-$625.3K-$4.1M
Interest income$136.2K$361.6K
Change in fair value of derivative liability-$313.8K
Change in fair value of Kineta merger holdback shares$1.6M
Loss on Kineta employee separation payments assumed from merger-$185.0K
Total Other Income (Expense)$1.7M-$4.0M
Net Loss-$30.1M-$21.7M
Series A Preferred cash dividend-$8.4K-$2.1K
Deemed dividend on warrant modifications$0-$965.2K
Net Loss attributable to common stockholders-$30.1M-$22.6M
Net Loss per share, basic-$0.63-$1.21
Net Loss per share, diluted-$0.63-$1.21
Weighted-average shares outstanding, basic47.9M shares18.7M shares
Weighted-average shares outstanding, diluted47.9M shares18.7M shares

Compare TuHURA Biosciences, Inc./NV with another company

Leadership

Who has led TuHURA Biosciences, Inc./NV, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jeffrey Bacha2013–2017
  2. Saiid Zarrabian2017–2020
  3. Robert Hoffman2021–2023
  4. James A. Bianco2024–now

President

  1. Jeffrey Bacha2013–2015
  2. Saiid Zarrabian2018–2020
  3. Robert Hoffman2021–2023

Chief financial officer

  1. Scott Praill2013–2022
  2. Robert Hoffman2023
  3. Dan Dearborn2024–now
201520202025
Board members and other officers (21)

Former names

  • Kintara Therapeutics, Inc.Aug 21, 2020 to Oct 22, 20242
  • DelMar Pharmaceuticals, Inc.Jan 23, 2013 to Aug 18, 20202
  • Berry Only Inc.Aug 17, 2010 to Jan 18, 20132

Timeline

  1. Oct 22, 2024New chief executive James A. Bianco becomes CEO12
  2. Nov 10, 2021New chief executive Robert Hoffman becomes CEO13
  3. Nov 7, 2017New chief executive Saiid Zarrabian becomes CEO14
  4. Feb 13, 2013New chief executive Jeffrey Bacha becomes CEO15

Filings

302 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 118 major events, 49 insider forms, 15 large holders, 2 private raises, 97 other. The latest 20:

  1. Sep 24, 20268-K EDGAR
  2. Sep 17, 20268-K EDGAR
  3. Sep 17, 20268-K/A EDGAR
  4. Sep 16, 20268-K EDGAR
  5. Sep 4, 20268-K EDGAR
  6. Aug 28, 2026SCHEDULE 13D/A EDGAR
  7. Aug 21, 20268-K EDGAR
  8. Aug 19, 20268-K EDGAR
  9. Aug 14, 202610-Q EDGAR
  10. Aug 14, 20268-K EDGAR
  11. Aug 13, 20268-K EDGAR
  12. Jul 29, 20268-K EDGAR
  13. Jul 9, 2026ARS EDGAR
  14. Jul 9, 2026DEFA14A EDGAR
  15. Jul 9, 2026DEF 14A EDGAR
  16. Jul 7, 20268-K EDGAR
  17. Jun 26, 2026PRE 14A EDGAR
  18. Jun 17, 20268-K EDGAR
  19. May 29, 20268-K EDGAR
  20. May 29, 20264 EDGAR

The 302 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 15 such filings since October 2021, the latest 10:

  1. Aug 28, 2026SCHEDULE 13D/A
  2. Feb 17, 2026SCHEDULE 13G
  3. Oct 31, 2025SCHEDULE 13G/A
  4. Aug 14, 2025SCHEDULE 13G/A
  5. Aug 14, 2025SCHEDULE 13G/A
  6. Jul 29, 2025SCHEDULE 13G
  7. Oct 25, 2024SC 13G
  8. Oct 25, 2024SC 13G
  9. Oct 25, 2024SC 13G
  10. Oct 25, 2024SC 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 27, 2025Raised $1.5 million in a private offering of equity Form D: $3 million offered in all Form D
  2. Jun 2, 2025Raised $2.2 million in a private offering of equity Form D: $12.6 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 90. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC2,267,901$5.3M0.0%+193,673
Northern Trust Corp1,621,042$3.8M0.0%+1,322,855
BlackRock, Inc.690,088$1.6M0.0%−1,760,168
Geode Capital Management, LLC484,219$1.1M0.0%−502,703
Millennium Management LLC454,535$1.1M0.0%New
Aqr Capital Management LLC424,600$993.6K0.0%−182,568
Vanguard Fiduciary Trust Co251,186$587.8K0.0%−35,947
Citadel Advisors LLC232,319$543.6K0.0%New
State Street Corp188,404$440.9K0.0%−324,509
Jane Street Group, LLC163,891$383.5K0.0%New
Apollon Wealth Management, LLC156,519$366.3K0.0%−1,491
Qube Research & Technologies Ltd145,595$340.7K0.0%New
Morgan Stanley143,257$335.2K0.0%+119,424
Goldman Sachs Group Inc131,768$308.3K0.0%+61,522
Bank of New York Mellon Corp121,662$284.7K0.0%−89,906
XTX Topco Ltd100,424$235.0K0.0%+88,911
WealthShield Partners, LLC91,530$214.2K0.0%No change
Aster Capital Management (DIFC) Ltd89,690$209.9K0.0%New
Captrust Financial Advisors88,373$206.8K0.0%New
Cetera Investment Advisers61,620$144.2K0.0%−78,624
UBS Group AG56,321$131.8K0.0%−5,745
Catalyst Funds Management Pty Ltd47,201$110.5K0.0%New
Brighton Jones LLC47,010$110.0K0.0%−1,575
Tudor Investment Corp Et Al45,115$105.6K0.0%New
Bank Of America Corp /de/42,506$99.5K0.0%−35,636

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

3 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jul 13, 2025Laurel M. LeeRepublican, HouseBuy$50,001 - $100,000−45.0%Report
Nov 25, 2024Laurel M. LeeRepublican, HouseBuy$1,001 - $15,000−74.7%Report
Oct 18, 2024Laurel M. LeeRepublican, HouseExchange$100,001 - $250,000Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38